Medicago touts promising H1N1 vaccine; U.S. adults still shun swine flu vaccine

Vaccine Research

Canada's Medicago says that its early-stage swine flu vaccine demonstrated promising results in a Phase I trial and will be ready for Phase II early next year. The developer is working on new vaccines that can be grown in genetically engineered plants, including tobacco. Story

Vical and the University of Washington have been awarded a patent for DNA vaccines guarding against herpes simplex virus type 2. They're collaborating on a preclinical program. Report

Regulators in the EU are recommending approval of Novartis' Menveo, a vaccine for meningitis. Report

The Fraunhofer USA Center for Molecular Biotechnology has won a $9.85 million grant from the Bill & Melinda Gates Foundation for work on a new malaria vaccine. Report

H1N1

It's much easier to find the swine flu vaccine these days, but more than half of all U.S. adults say in a new poll that they still don't want it. Story

Australian researchers have determined that a single dose of the H1N1 vaccine can protect schoolchildren, offering a strategy for containing the virus. Story

After waiting their turn, President Barack Obama and his wife were vaccinated against swine flu. Story

Suggested Articles

Merck & Co. inked a series of deals to advance three COVID-19 projects, trailing some of its large pharma peers into the industrywide research effort.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.